Microfluidic technology to isolate tumoricidal T-cells from peripheral blood
微流控技术从外周血中分离杀肿瘤T细胞
基本信息
- 批准号:10613173
- 负责人:
- 金额:$ 21.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAdoptive Cell TransfersAffinityAutologousAutologous Tumor CellBiomedical EngineeringBloodBlood CellsCD8-Positive T-LymphocytesCancer PatientCell AdhesionCell DensityCell FractionCell LineCell SeparationCellsCellular immunotherapyClinicalClinical OncologyCollaborationsDevice DesignsDevicesDimensionsExposure toGoalsHeterogeneityImmunologyInterferon Type IIKnowledgeLeukocytesLymphocyteMART-1 Tumor AntigenMajor Histocompatibility ComplexMalignant NeoplasmsMelanoma CellMethodsMicrofluidic MicrochipsMicrofluidicsMolecularPatientsPeptidesPerfusionPeripheral Blood LymphocytePeripheral Blood Mononuclear CellPopulationPreparationProcessPublishingResearch PersonnelSamplingSourceSurfaceSurgical OncologyT cell receptor repertoire sequencingT cell therapyT-LymphocyteTechnologyTumor AntigensTumor-DerivedTumor-Infiltrating Lymphocytesanticancer researchantigen-specific T cellscancer cellcancer immunotherapycostimproved outcomeinterestmelanomamicrofluidic technologyneoplastic cellnew technologynovel therapeutic interventionperipheral bloodpersonalized medicineprogramsstatisticssuccesstechnology developmenttumor
项目摘要
PROJECT SUMMARY
Adoptive cell transfer (ACT) using ex vivo expanded anti-tumor T-cells has garnered significant interest due to
successes in treating melanoma and other cancers. This is a highly personalized therapy, in which autologous
T-cells that can target the tumors are required. However, finding cells that specifically target tumors remains a
major hurdle for the widespread application of T-cell based ACT therapies. The current methods of lymphocyte
enrichment result in modest increases in tumoricidal T-cells with little control over the clonal heterogeneity. A
technology that overcomes these challenges would significantly lower the barriers (e.g., reduce cost, reduce
off-target effects) for broad dissemination of ACT therapies. The primary goal of this project is to develop a
separation technology to enrich a population of lymphocytes with tumoricidal T-cells based on their capacity to
recognize autologous tumor antigens. The premise of our microfluidic technology is that tumoricidal T-cells can
be separated from a bulk leukocyte population when exposed to tumor-derived peptide-major histocompatibility
complex I under optimal flow conditions. The specific aims are to: 1) Develop a microfluidic device to enrich a
population of lymphocytes with antigen specific T-cells, and 2) Demonstrate the capacity of the microfluidic
platform to enrich patient-derived Peripheral Blood Mononuclear Cells with tumoricidal T-cells using patient-
matched tumor cells. Accomplishing our primary goal will create a potentially disruptive technology that could
pave way for wide-spread application of T-cell based ACT therapies, and the agnostic feature (i.e., no a priori
knowledge of tumor antigen(s) is required) of the technology would make it broadly applicable for a
personalized medicine approach to a range of cancers.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Venktesh Shirure其他文献
Venktesh Shirure的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}